Primary liver cancer is currently the fourth most common malignant tumor in China and the second leading cause of tumor mortality in Central Europe, posing a serious threat to the lives and health of the Chinese people. At present, the treatment plan for liver cancer is mainly surgical treatment, but the prognosis of many patients is unsatisfactory. Many patients even lose the opportunity for surgery when diagnosed. At a time when the treatment of liver cancer was stagnant, the emergence of molecular targeted chemotherapy drugs brought new hope to liver cancer patients. For example, the first to appear sorafenib brought revolutionary progress to the treatment of advanced liver cancer. However, due to limited understanding of the molecular typing of liver cancer, it was impossible to screen molecular targeted chemotherapy drugs for those patients, resulting in significant differences in patient responses to targeted therapy. Therefore, establishing a molecular typing scheme for liver cancer to guide clinical targeted therapy is particularly important. This review will briefly discuss the latest progress in molecular typing and targeted therapy for liver cancer.

Zhou Lin, Zhou Jun. Research Progress in Molecular Typing and Targeted Therapy of Liver Cancer. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 10: 112-117. https://doi.org/10.25236/IJFM.2023.051018.

[1] Zhou Maigeng, Wang Haidong, Zeng Xinying, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990- 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. 

[2] Chen Wanqing, Zheng Rongshou, Baade Peter D, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016, 66(2):115-132.

[3] Catherine de Martel, Damien Georges, Freddie Bray, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. The Lancet Global Health, 2020, 8(2): e180-e190.

[4] Chen Wanqing, Sun Kexin, Zheng Rongshou, et al. Cancer incidence and mortality in China, 2014 [J]. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2018, 30(1):1-12.

[5] Villanueva A. Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 380:1450-1462.

[6] Wanshui Yang, Xufen Zeng, Zhining Liu, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence[J]. British Journal of Nutrition, 2020, 124(3):330-340. 

[7] Giancarlo Spinzi, Silvia Paggi. Sorafenib in Advanced Hepatocellular Carcinoma[J]. The New England Journal of Medicine, 2008, 359(23):2497-2499. 

[8] T. R. Golub, D. K. Slonim, P. Tamayo, et al. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring[J]. Science, 1999, 286(5439):531-537. 

[9] Huang Yongta, Mo Xianglan. Research progress of regulation mechanisms in miRNA and tumor metastasis [J]. Chinese Journal of New Clinical Medicine, 2020, 13(1):94-98. 

[10] Wilhelm Scott M, Carter Christopher, Tang Liya, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. [J]. Cancer research, 2004, 64(19):7099-7109. 

[11] Yakes F Michael, Chen Jason, Tan Jenny, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.[J]. Molecular cancer therapeutics, 2011, 10(12):2298-2308. 

[12] Luo Xiangyuan, Wu Kongming, He Xingxing, et al. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets[J]. Journal of experimental & clinical cancer research: CR, 2021, 40(1):172-172.

[13] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34. 

[14] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391:1163-1173. 

[15] Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis[J]. Cancer Med, 2019, 8(1):137-146. 

[16] Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity [J]. Int J Cancer, 2011, 129(1), 245-255. 

[17] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double- blind, placebo- controlled, phase 3 trial [J]. Lancet, 2017, 389(10064):56-66. 

[18] Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth [J]. Mol Cancer Ther, 2011, 10(12), 2298-2308. 

[19] Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. New Engl J Med, 2018, 379(1):54-63.